KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ginkgo Bioworks Holdings (DNA) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Ginkgo Bioworks Holdings (DNA) over the last 6 years, with Q3 2025 value amounting to 207.05%.

  • Ginkgo Bioworks Holdings' EBITDA Margin fell 1459400.0% to 207.05% in Q3 2025 from the same period last year, while for Sep 2025 it was 187.04%, marking a year-over-year increase of 1102800.0%. This contributed to the annual value of 242.39% for FY2024, which is 1110600.0% up from last year.
  • Per Ginkgo Bioworks Holdings' latest filing, its EBITDA Margin stood at 207.05% for Q3 2025, which was down 1459400.0% from 116.52% recorded in Q2 2025.
  • In the past 5 years, Ginkgo Bioworks Holdings' EBITDA Margin ranged from a high of 34.37% in Q3 2021 and a low of 1134.55% during Q4 2021
  • Over the past 5 years, Ginkgo Bioworks Holdings' median EBITDA Margin value was 249.97% (recorded in 2024), while the average stood at 354.45%.
  • Within the past 5 years, the most significant YoY rise in Ginkgo Bioworks Holdings' EBITDA Margin was 9638200bps (2022), while the steepest drop was -9785300bps (2022).
  • Over the past 5 years, Ginkgo Bioworks Holdings' EBITDA Margin (Quarter) stood at 1134.55% in 2021, then soared by 85bps to 170.73% in 2022, then plummeted by -249bps to 596.49% in 2023, then skyrocketed by 58bps to 249.97% in 2024, then grew by 17bps to 207.05% in 2025.
  • Its EBITDA Margin stands at 207.05% for Q3 2025, versus 116.52% for Q2 2025 and 186.27% for Q1 2025.